BioCentury | Mar 7, 2020
Emerging Company Profile

Kira: depleting activated dendritic cells

First-in-class mAbs against activated dendritic cells from Australian newco Kira could block the inflammation and immune response associated with GvHD and autoimmune diseases without the risk of infection that accompanies broad immunosuppression. Founding CEO Dan...
BC Innovations | Feb 22, 2019
Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
BC Innovations | Nov 6, 2018
Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays; gene profiling; tissue markers Gene profiling coupled with cell-based assays of patient samples could help predict drug responses in AML patients. In tumor samples from 363 patients, whole-exome sequencing plus genotyping of...
BC Extra | Jan 27, 2018
Company News

FDA to review its pediatric exclusivity decision for Amgen's Sensipar

A federal judge ordered FDA to address whether its decision to grant pediatric exclusivity to Ortho Tri-Cyclen norgestimate/ethinyl estradiol from the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) is consistent with its decision...
BC Innovations | Jan 11, 2018
Emerging Company Profile

Next, after T cells

PD-1 pioneer Lieping Chen is solving some of the unanswered questions from that breakthrough with his new company, NextCure Inc. The idea is to use myeloid cell factors to boost the effectiveness of other T...
BC Week In Review | Jul 13, 2017
Clinical News

FDA approves Orencia for psoriatic arthritis

FDA approved Orencia abatacept from Bristol-Myers Squibb Co. (NYSE:BMY) to treat psoriatic arthritis. The product is a CTLA-4 (CD152)-Ig fusion protein available in both IV and subcutaneous formulations. It is already approved in the U.S....
BC Week In Review | Jul 6, 2017
Clinical News

EMA's CHMP recommends Orencia in psoriatic arthritis

EMA’s CHMP recommended a label expansion for Orencia abatacept (ONO-4164IV) from Bristol-Myers Squibb Co. (NYSE:BMY) to include treatment of active psoriatic arthritis in adults for whom previous disease-modifying anti-rheumatic drug (DMARD) therapy, including methotrexate , has...
BC Week In Review | Jun 22, 2017
Clinical News

Ono, BMS submit supplemental application in Japan for Orencia to treat JIA

Ono Pharmaceutical Co. Ltd. (Tokyo:4528) and Bristol-Myers Squibb Co. (NYSE:BMY) submitted a supplemental application in Japan for IV Orencia abatacept (ONO-4164IV) to treat active polyarticular juvenile idiopathic arthritis (JIA). The CTLA-4 (CD152)-Ig fusion protein is...
BC Innovations | Mar 15, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Chikungunya virus Mouse studies suggest Gilenya fingolimod, Orencia abatacept and Xeljanz tofacitinib could help treat Chikungunya infection. Testing of a total of 11 drugs in mouse models of Chikungunya infection by two independent groups...
Items per page:
1 - 10 of 74